MIDDLETOWN, PA, May 8, 2017 – MacuLogix®, Inc., an innovator in the early detection and tracking of age-related macular degeneration, has appointed Armond Dantino as Vice President of Sales, effective today. As a key member of the company’s management team, Mr. Dantino will be responsible for all direct sales and business development functions for MacuLogix.
William McPhee, President and CEO of MacuLogix, said, “Armond is a high-energy leader with an impressive history of recruiting and mentoring the best and the brightest sales talent and forging them into a team. He has exceeded every sales goal put in front of him, delivering value to his employers and his customers.” McPhee added, “Most importantly, he has a true passion for our company’s vision to eliminate blindness caused by age-related macular degeneration.”
Mr. Dantino is a 28-year veteran of medical instrument companies with US and international experience. He has consistently led corporate growth in a variety of sales strategy and leadership positions with Forus Health, Fukuda Denshi, Heidelberg Engineering, Draeger Medical, Cardinal Health/Alaris and Johnson & Johnson. He earned a BS in nursing from Western Connecticut State University and an MBA in international management from Columbia Southern University.
“I am extremely excited to join such a dynamic and progressive company as MacuLogix. It is my sincere hope that I can accelerate the adoption of the AdaptDx® by all practitioners and help to eliminate blindness caused by age-related macular degeneration,” said Mr. Dantino.
MacuLogix, Inc. is an innovator in the early detection and tracking of age-related macular degeneration (AMD). The company’s AdaptDx dark adaptometer is the first practical device for detecting AMD at least three years earlier than other technologies. The AdaptDx is an easy-to-use functional test that enables doctors to detect AMD and monitor disease progression in order to preserve vision and maintain quality of life with proactive intervention.